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Background: To investigate potential associations of serum prolactin concentration (PRL) with metabolic syndrome
(MetS) and type 2 diabetes mellitus (T2DM), previously observed in small and selected study samples, in a large
population-based cohort.
Methods: Data from 3,993 individuals (2,027 women) aged 20-79 years from the population-based Study of Health
of Pomerania (SHIP) were used to analyse cross-sectional and longitudinal associations of PRL with MetS and T2DM
risk in age- and multivariable-adjusted Poisson regression models. PRL were log-transformed and modelled as
continuous (per standard deviation (SD) increase) and categorical predictor (sex-specific quartiles) variable,
separately for men and woman.
Results: Cross-sectional analyses showed an inverse association between low PRL concentrations and prevalent
T2DM risk in men and women after multivariable-adjustment (men: Q1 vs. Q4: relative risk (RR), 1.55; 95%
confidence interval (CI), 1.13 – 2.14; women: Q1 vs. Q4: RR, 1.70; 95% CI, 1.10 – 2.62). Likewise, higher PRL
concentrations were associated with significantly lower T2DM risk (RR per SD increase in log-PRL: 0.83; 95% CI,
0.72 – 0.95 in men, and 0.84; 95% CI, 0.71 – 0.98 in women, respectively). An inverse association between PRL and
MetS risk was not retained after multivariable adjustment. Longitudinal analyses yielded no association of PRL with
incident MetS or T2DM.
Conclusion: The present study is the first large population-based study reporting a cross-sectional inverse
association between PRL and prevalent T2DM in both genders. But the absent longitudinal associations do not
support a causal role of PRL as a risk factor of incident MetS or T2DM.Background
Prolactin (PRL) is a pituitary hormone essential for vari-
ous physiological functions in the human body [1-3]. It is
not only important for the initiation and maintenance of
lactation, but seems to be also involved in reproduction,
growth and development, osmoregulation, immune regu-
lation, brain function, behaviour, and metabolism [1-3].
These different functions of PRL can only be fulfilled due
to the fact that the PRL receptor is expressed in different
tissues and cells such as lymphoid cells, endometrium,
prostate, and adipocytes [1-3].* Correspondence: robin.haring@uni-greifswald.de
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reproduction in any medium, provided the orThe metabolic syndrome (MetS), a cluster of car-
diometabolic risk factors including obesity, hypertrigly-
ceridemia, hypertension, and insulin resistance [4,5], is
often associated with type 2 diabetes mellitus (T2DM)
[1]. Although previous investigations about the potential
effects of PRL in T2DM and its complications are scarce,
existing experimental studies suggest an influence of
PRL on T2DM via its metabolic effects on adipose tissue
[2,3], development and growth of pancreatic ß-cells
[6,7], insulin resistance [3,8], and lipid metabolism [3,9].
The ability of PRL to stimulate insulin [6] and suppress
adiponectin as well as interleukin-6 release further sug-
gests a potential role in the manifestation of insulin re-
sistance [2]. But although these studies support the view
that PRL promotes the growth and survival of pancreatic
ß-cells and supports insulin secretion [6,7], other studies
were not able to detect any correlation between PRL and
metabolic disturbances [10].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients showed an association between low PRL concen-
trations and adverse cardiovascular risk profiles and e-
vents [11]. However, in most of these previous studies
[10,11] the correlation between PRL and cardiometabolic
risk factors including MetS or T2DM were not the main
focus. Furthermore, previous studies were conducted in
comparably small and selected patient populations with-
out consideration of major confounding factors. There-
fore, we aimed to investigate potential associations of PRL
with MetS and T2DM using a large, representative sample
of 3,993 individuals from the population-based longitu-
dinal cohort Study of Health in Pomerania (SHIP).
Methods
Study population
The SHIP is a population-based cohort study in West
Pomerania, a region in north-eastern Germany. Details
regarding the design, recruitment, and procedures of the
SHIP study have been published previously [12]. In brief,
from the total population of West Pomerania comprising
213,057 inhabitants, a two-stage stratified cluster sample
of adults aged 20-79 years was drawn in 1996. The net
sample (without migrated or deceased persons) comprised
6,265 eligible subjects. Only individuals with German ci-
tizenship and main residency in the study area were in-
cluded. All subjects received a maximum of three written
invitations. In cases of non-response, letters were followed
by repeated phone calls or by home visits if contact by
phone was not possible [13]. After written informed con-
sent was obtained, 4,308 (2,192 women) participants were
examined (response 68.8%) between 1997 and 2001. Dur-
ing the five-year follow-up, 3,300 (1,711 women) partici-
pants were re-examined (response 83.6%) between 2002
and 2006. The study conformed to the principles of the
Declaration of Helsinki and the Ethics Committee of the
University of Greifswald approved the protocol. Out of
4,308 baseline participants, we excluded individuals with
missing PRL data (N = 169), measured PRL >100.0 μg/l
(N = 16), pregnancy (N = 8), pituitary disease (N = 1), and
missing covariate data (N = 121), yielding a final study
sample of 3,993 individuals (2,027 women).
Measures
Information about socio-demographic characteristics
and health-related lifestyle including smoking habits
(categorized into current, former, and never-smokers),
educational level (< 10, = 10, or > 10 years at school),
parity (number of children), physical activity (< 1 h/week
physical training during summer or winter) and alcohol
consumption were collected by personal interviews.
Waist circumference was measured to the nearest0.1 cm using an inelastic tape midway between the lower
rib margin and the iliac crest in the horizontal plane,
with the subject standing comfortably with weight dis-
tributed evenly on both feet. Height and weight were
measured for the calculation of body mass index (BMI)
(weight [kg]/height [m]2). After a resting period of at
least five minutes, systolic and diastolic blood pressure
was measured three times on the right arm of seated
participants with an oscillometric digital blood pressure
monitor (HEM-705CP, Omron Corporation, Tokyo,
Japan). The interval between the readings was three mi-
nutes. The mean systolic and diastolic blood pressure
was calculated from the second and third measurement
[14]. Menopausal status (pre- and post-menopausal) was
defined according to a previously established definition
from our cohort: pre-menopausal: all women < 40 years
of age and between 40 – 60 years who reported men-
strual cycle; post-menopausal: all women ≥ 60 years of
age and all women between 40 – 60 years who reported
no menstrual cycle [15].
Serum high-density lipoprotein (HDL) cholesterol con-
centrations were measured photometrically at baseline
(Hitachi 704, Roche, Mannheim, Germany), whereas
follow-up HDL concentrations were quantified by lipid
electrophoresis (HELENA SAS-3 system, Helena 7 Bio-
Sciences Europe, Tyne & Wear, UK). To ensure compara-
bility in the longitudinal HDL analyses, we used baseline
HDL concentrations as the reference and calculated cor-
rected follow-up HDL concentrations based on a previ-
ously published conversion formula [16]. Doing so, we
found that the average HDL concentrations produced by
the two methods were virtually identical, suggesting that
the differences in HDL will be small within the range of
practical relevance [17]. Serum triglycerides and glucose
concentrations were determined enzymatically using
reagents from Roche Diagnostics (Hitachi 717, Roche
Diagnostics, Mannheim, Germany). Glycated hemoglobin
(HbA1c) was determined by high-performance liquid
chromatography (Bio-Rad, Munich, Germany). During the
course of the study, the inter-assay coefficient of variation
for HbA1c was 2.76% in the low pool and 1.38% in the
high pool. All assays were performed according to the
manufacturers’ recommendations by skilled technical
personnel and internal quality controls were analyzed
daily. In addition, the laboratory participates in official
quarterly German external proficiency testing programs.
T2DM was defined based on self-reported physician’s
diagnosis or use of antidiabetic medication (ATC code
A10) in the last seven days, or HbA1c concentrations >
6.5%. Diagnostic criteria for the assessment of MetS com-
ponents were defined according the Joint Scientific State-
ment to harmonize MetS [18] and modified for the use of
non-fasting blood samples, as previously established in
SHIP [19-22] and other large cohort studies [23]:
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2. Elevated non-fasting glucose: ≥ 8.0 mmol/l or
antidiabetic treatment (ATC codes A10A, A10B);
3. Decreased HDL cholesterol: men < 1.0 mmol/l,
women < 1.3 mmol/l, or lipid-lowering treatment
(ATC C10AB, A10AD);
4. Elevated non-fasting triglycerides: ≥ 2.3 mmol/l or
lipid-lowering treatment (ATC C10AB, A10AD);
5. Elevated blood pressure: ≥ 130/85 mmHg or self-
reported antihypertensive drug treatment.
Participants fulfilling at least three out of these five
components were assigned to MetS.
Serum PRL concentrations were measured from frozen
sera of baseline participants. Non-fasting blood samples
were drawn from the cubital vein in the supine position
between 7.00 a.m. and 7.00 p.m. Samples were stored at -
80°C until analysis using a chemiluminescent immuno-
metric assay on an Immulite 2500 analyzer (Ref. L5KPR,
DPC Biermann GmbH, Bad Nauheim, Germany). An ali-
quot of two alternating levels of a third party commercial
control material (Bio-Rad Lyphochek Immunoassay Plus
Control, lot 40151 and lot 40152; Bio-Rad, Munich,
Germany) was included in each series in single determin-
ation. During the course of the study the inter-assay coef-
ficient of variation was 5.6% with a systematic deviation of
-4.3% at the 6.3 μg/l level, and 4.3% with a systematic de-
viation of -6.4% at the 14.5 μg/l level. The analytical sensi-
tivity was 0.5 μg/l by an effective measurement range of
0.5 – 150 μg/l.
Statistical analysis
Categorical data are expressed as percentage and con-
tinuous data as median (p25th, p75th). Sex-related differ-
ences were tested using the χ2 test (categorical data) and
Mann-Whitney-U test (continuous data). We log-
transformed the highly skewed PRL variable to achieve
normality. To analyse cross-sectional and longitudinal
associations of PRL with MetS and T2DM, we imple-
mented age- and multivariable-adjusted Poisson regres-
sion models with robust standard errors and report the
relative risks (RR) and their 95% confidence intervals
(95% CI) per SD increase in log-PRL and for sex-specific
PRL quartiles (reference: quartile four). Longitudinal in-
cidence analyses were performed only in individuals
without MetS and T2DM at baseline, respectively. P for
trend test was conducted by including PRL quartiles as
an ordinal score into the regression models. Covariates
adjusted for in multivariable regression models included
age, BMI, smoking status, physical activity, educational
level, and alcohol consumption. All analyses were
performed separately in men and women.
Several sensitivity analyses were performed. In
women, we additionally adjust multivariable regressionmodels for menopausal status and parity. On the basis
of ATC codes for metoclopramide (A03FA01, A03FA03,
N02CX59), cimetidine (A02BA01), reserpine (C02LA01),
methyldopa (C02AB), and psychoanaleptics (ATC-code
N06), we excluded 184 individuals indicative of these PRL
influencing medications [24] and repeated the multivari-
able regression models accordingly. Furthermore, we used
inverse probability weights to adjusted our longitudinal
analyses for possible non-response bias from drop-out
between the baseline and follow-up examination [25].
Finally, we additionally adjusted the multivariable models
for blood sampling time to evaluate the potential impact
of the diurnal cycle in PRL secretion on the revealed esti-
mates. Two-sided probability values < 0.05 were consid-
ered statistically significant. All the statistical analyses
were performed using Stata 11.0 (Stata Corporation,
College Station, TX, USA).
Results
Comparing the baseline characteristics of the study sam-
ple by sex, men showed significantly lower PRL concen-
trations and a higher cardiometabolic risk factor level
(with regard to smoking, alcohol consumption, BMI,
blood pressure, lipid levels and parameters of glycemic
control) than women (Table 1). Also the prevalence of
MetS (34.0% vs. 22.2%) and T2DM (12.6% vs. 9.0%) was
higher in men compared to women.
Cross-sectional age-adjusted regression models showed
an inverse association between PRL and MetS risk in
women (Q1 vs. Q4: RR, 1.32; 95% CI, 1.04 – 1.66), but not
in men (Q1 vs. Q4: RR, 1.15; 95% CI, 0.97 – 1.37). This
sex-specific association was not retained after multiva-
riable adjustment (Table 2). Low PRL concentrations
were consistently associated with T2DM in age- and
multivariable-adjusted regression models (men: Q1 vs.
Q4: RR, 1.55; 95% CI, 1.13 – 2.14; women: Q1 vs. Q4: RR,
1.70; 95% CI, 1.10 – 2.62). Furthermore, p for trend ana-
lyses showed a progressive inverse relationship across PRL
quartiles. Likewise, higher PRL concentrations were asso-
ciated with a significantly lower T2DM risk (RR per SD
increase in log-PRL: 0.83; 95% CI, 0.72 – 0.95 in men, and
0.84; 95% CI, 0.71 – 0.98 in women, respectively).
After a median follow-up time of 5.0 years (range 4.4 –
8.5 years) 3,078 individuals (1,589 women) were repea-
tedly examined. Among the individuals without the
respective condition at baseline, 27.7% developed incident
MetS and 5.3% incident T2DM. Longitudinal analyses
revealed a significant trend of lower PRL concentrations
with increasing number of MetS components in women
(p = 0.033), but not in men (p = 0.331) (Figure 1). Multi-
variable regression models showed no association of PRL
with incident MetS and T2DM (Table 2). The conducted
sensitivity analyses with 1) additional adjustment for
menopausal status and parity, 2) exclusion of individuals
Table 1 Baseline characteristics of the study population stratified by sex
Men Women
p-value*
(N = 1,966) (N = 2,027)
Age, years 52.1 (37.4; 65.3) 49.5 (36.0; 62.3) <0.001
Serum prolactin, μg/l 4.9 (3.6; 6.9) 6.5 (4.5; 9.4) <0.001
Current smoker,% 33.5 26.9 <0.001
Physical activity,% 41.0 43.4 0.130
Alcohol consumption, g/d 11.9 (1.5; 27.9) 2.5 (0.0; 7.2) <0.001
Educational level
<0.001
< 10 years 42.7 37.8
= 10 years 39.8 46.8
> 10 years 17.5 15.3
Parity, N NA 2 (1, 3) NA
Body mass index, kg/m2 27.3 (24.9; 29.9) 26.1 (22.8; 30.2) <0.001
Waist circumference, cm 95.2 (87.5; 102.9) 81.5 (72.8; 92.1) <0.001
Systolic blood pressure, mmHg 140.5 (129.5; 153.0) 127.0 (114.5; 143.0) <0.001
Diastolic blood pressure, mmHg 85.0 (78.0; 93.0) 80.5 (73.5; 87.5) <0.001
Serum total cholesterol, mmol/l 5.7 (4.9; 6.4) 5.7 (4.9; 6.5) 0.811
Serum triglycerides, mmol/l 1.7 (1.2; 2.6) 1.3 (0.9; 1.9) <0.001
Serum LDL cholesterol, mmol/l 3.6 (2.8; 4.3) 3.4 (2.7; 4.2) 0.002
Serum HDL cholesterol, mmol/l 1.2 (1.0; 1.5) 1.5 (1.3; 1.8) <0.001
Serum glucose, mmol/l 5.4 (5.0; 6.0) 5.2 (4.8; 5.7) <0.001
Glycated hemoglobin A1c,% 5.4 (5.0; 5.9) 5.2 (4.8; 5.7) <0.001
Metabolic syndrome,% 34.0 22.2 <0.001
Type 2 diabetes mellitus,% 12.6 9.0 <0.001
Data are given as percentages or median (p25th; p75th). NA, not applicable; LDL cholesterol, low-density lipoprotein cholesterol; HDL cholesterol, high-density
lipoprotein cholesterol.
* Differences between men and women were tested using χ2 test (categorical data) and Whitney-Mann-U Test (continuous data).
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inclusion of ‘drop-out’ weights and 4) additional adjust-
ment for blood sampling time showed no impact on the
overall estimates (data not shown).
Discussion
To our knowledge, this is the first population-based
study to show a cross-sectional inverse association bet-
ween PRL and T2DM risk in both men and women.
Using a large sample of 3,993 individuals from the gen-
eral population, age- and multivariable-adjusted regres-
sion models detected an inverse association between low
PRL concentrations and increased risk for prevalent
T2DM.
These findings are in line with previous observational
studies [11,26,27] of the relationship between PRL and
T2DM. Among those, the only large-scaled study was
conducted in 2,351 male patients with sexual dysfunc-
tion, in whom low PRL concentrations were associated
with an increased number of MetS factors [26]. Similarly
to ours, that study [26] and its subsequent follow-up[11] showed an inverse association between serum PRL
concentrations and prevalent T2DM. However, since
both studies based on male patient data, the comparabi-
lity with the present population-based findings is quite
limited. Furthermore, a cross-sectional study in 345
healthy volunteers aged 30-55 years showed a negative
association of PRL with insulin resistance and a doubled
risk of prevalent MetS per SD decrease in PRL [27].
Evidence from cross-sectional patient-based studies in
drug naive schizophrenia patients suggests that high
dopamine and subsequently low PRL concentrations
[28,29] are related to an increased T2DM risk, including
insulin resistance and impaired fasting glucose [30].
Thus, one may speculate if common anti-psychotics
could probably protect from T2DM onset and progres-
sion by increasing PRL concentrations through the in-
hibition of the D2 receptor [31]. However, since
previous studies [28-30] were exclusively cross-sectional,
cause and effect in the association of PRL with T2DM
are difficult to determine. For example, a small interven-
tional study in turn suggests insulin secretion as the
major determinant of PRL release [9].
Table 2 Cross-sectional and longitudinal associations of serum prolactin with metabolic syndrome and type 2 diabetes
mellitus
Metabolic syndrome Type 2 diabetes mellitus




















0.95 (0.89; 1.02) 0.95 (0.89; 1.01) 1.05 (0.95; 1.15) 1.04 (0.95; 1.14) 0.84 (0.73; 0.96)* 0.83 (0.72; 0.95)* 1.20 (0.98; 1.47) 1.19 (0.96; 1.47)
Quartiles
(Q4 Ref.)
Q1 1.15 (0.97; 1.37) 1.15 (0.98; 1.35) 0.83 (0.64; 1.06) 0.87 (0.68; 1.10) 1.55 (1.12; 2.13)* 1.55 (1.13; 2.14)* 0.71 (0.41; 1.23) 0.78 (0.45; 1.35)
Q2 1.06 (0.89; 1.28) 1.03 (0.87; 1.22) 0.94 (0.74; 1.19) 0.94 (0.75; 1.18) 1.14 (0.81; 1.61) 1.11 (0.79; 1.56) 0.73 (0.42; 1.26) 0.78 (0.45; 1.33)
Q3 1.04 (0.87; 1.25) 1.02 (0.85; 1.21) 0.91 (0.72; 1.16) 0.94 (0.75; 1.18) 0.92 (0.63; 1.33) 0.92 (0.64; 1.33) 0.76 (0.44; 1.32) 0.72 (0.41; 1.27)




0.92 (0.85; 1.00) 0.97 (0.90; 1.05) 0.89 (0.79; 1.00) 0.92 (0.83; 1.02) 0.81 (0.68; 0.95)* 0.84 (0.71; 0.98)* 1.09 (0.82; 1.45) 1.13 (0.89; 1.44)
Quartiles
(Q4 Ref.)
Q1 1.32 (1.04; 1.66)* 1.11 (0.89; 1.39) 1.26 (0.95; 1.68) 1.15 (0.86; 1.53) 1.89 (1.21; 2.96)* 1.70 (1.10; 2.62)* 0.88 (0.44; 1.78) 0.73 (0.37; 1.43)
Q2 1.13 (0.89; 1.44) 1.04 (0.83; 1.32) 1.22 (0.91; 1.63) 1.16 (0.87; 1.54) 1.82 (1.15; 2.86)* 1.69 (1.09; 2.63)* 0.81 (0.39; 1.68) 0.75 (0.37; 1.50)
Q3 1.11 (0.86; 1.44) 1.07 (0.83; 1.32) 0.73 (0.51; 1.04) 0.78 (0.55; 1.11) 1.29 (0.77; 2.16) 1.26 (0.76; 2.09) 1.00 (0.48; 2.06) 1.08 (0.53; 2.20)
P for Trend 0.016 0.399 0.013 0.106 0.001 0.007 0.633 0.224
* p < 0.05; SD, standard deviation. The multivariable model was adjusted for age, body mass index, smoking status (three categories), physical activity, educational
level (three categories), and alcohol consumption.
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studies related alterations of serotonergic pathways
caused by low PRL concentrations to the pathogenesis
of MetS [27,32]. Furthermore, PRL-receptor deficient
mice show an impaired development of pancreatic ß-Figure 1 Boxplots for median baseline prolactin concentrations (25th
metabolic syndrome (MetS) components, separately for men and wom
for prolactin concentrations across number of MetS components at follow-cells, finally leading to a blunted insulin response and
mild glucose intolerance [7]. In contrast to our find-
ings, studies including pathological hyperprolactinemia
caused by PRL-secreting tumors (prolactinomas)
showed that, after treatment with dopamine agonists,and 75th percentile) according to the follow-up number of
en. One-way analysis of variance showed a significant inverse trend
up in women (p = 0.033), but not in men (p = 0.331).
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sensitivity [33,34].
These results, however, were collected in small patient-
based samples with clinically confirmed prolactinoma and
serum PRL concentrations outside the reference range,
thus limiting its transferability to the general population.
On contrary, HOMA-IR, as a measure of insulin resis-
tance, did not change after treatment with dopamine ago-
nists [33], and PRL concentrations did not correlate with
HOMA-IR change or decrease in glucose, respectively
[8,34]. Interestingly, a previous cross-sectional study in
obese non-prolactinoma patients showed similar absent
correlations of PRL with insulin, HOMA-IR, and glucose
levels [10]. Available in-vitro studies rather suggest an
influence of prolactin on ß-cell secretion via increased glu-
cokinase activity [35], improved ß-cell specific survival
[36,37], or inhibition of intrinsic ß-cell apoptosis [38].
However, to provide the necessary level of detail to eluci-
date the exact mechanisms of PRL on different tissues and
its impact on cardiometabolic risk factors further experi-
mental in-vitro research is needed.
We previously published findings from our study sug-
gesting a positive association of PRL with biomarkers of
inflammation [39] and mortality (cardiovascular and all-
cause mortality) [40], as well as an inverse association of
PRL with cardiac remodelling [41]. However, these ob-
servational findings from our and other studies do not
provide consistent risk associations, suggesting the need
for further investigations into the potential role of PRL
as cardiometabolic risk marker.
For the interpretation of the present study, the follo-
wing strengths and limitations need to be considered.
Major strengths include the large sample, the longitu-
dinal study design, and a broad age range. Furthermore,
comprehensive sensitivity analyses were conducted to
assess the validity of our findings. An important limita-
tion of this study includes the reliance on single serum
PRL measurements based on non-fasting blood samples,
which is not adapted to the pulsatile release of PRL. But
it was shown that the pulsatile secretion occurs mostly
during the night and is relatively constant between
9.00 a.m. and 5.00 p.m. [42]. Further limitations arise
from the Caucasian study sample, which restricts the
generalizability of our results. Finally, we did not exclude
other endocrine diseases, which possibly trigger T2DM
including hyperthyroidism [43,44], acromegaly and the
Cushing Syndrome [45].
However, given the inherent limitations of observational
research [46], the definite role of serum PRL concentra-
tions as a risk factor or risk marker can not be elucidated
based on epidemiological data alone. Previous associations
between serum PRL concentrations and disease risk ob-
served in clinical study samples, but not in the general
population, suggest PRL rather as specific disease markerthan as causal risk factor for MetS and T2DM. Thus, its
application and significance in daily clinical practice is
very limited to date.
Conclusions
In summary, this is the first population-based study to
show low PRL concentrations related to a higher T2DM
risk in both genders. But given the variable associations
between PRL and T2DM, but not with MetS, together
with the absent longitudinal associations with both out-
comes, the present study does not support PRL as a causal
cardiometabolic risk factor. Therefore, we hypothesize
PRL rather as a marker of the complex multi-level alte-
rations involved in the onset and progression of T2DM.
However, to further elucidate the potential role of PRL in
the context of this complex interplay, further observa-
tional as well as interventional research is needed.
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